Document and Entity Information
Document and Entity Information | Mar. 29, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | Aptevo Therapeutics Inc. (“Aptevo” or the “Company”) is filing this Amendment No. 1 on Form 8-K/A (“Amendment”) to supplement our Form 8-K originally filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022. The Company is filing this Amendment to clarify that the monotherapy patient reported yesterday was the second patient in the on-going Phase 1b expansion trial who proceeded to transplant after receiving APVO436 and experiencing clinical benefit. |
Document Period End Date | Mar. 29, 2022 |
Entity Registrant Name | APTEVO THERAPEUTICS INC. |
Entity Central Index Key | 0001671584 |
Entity Emerging Growth Company | false |
Entity File Number | 001-37746 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 81-1567056 |
Entity Address, Address Line One | 2401 4th Avenue |
Entity Address, Address Line Two | Suite 1050 |
Entity Address, City or Town | Seattle |
Entity Address, State or Province | WA |
Entity Address, Postal Zip Code | 98121 |
City Area Code | 206 |
Local Phone Number | 838-0500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value |
Trading Symbol | APVO |
Security Exchange Name | NASDAQ |